Eli Lilly will lose nearly 1,000 sales representatives nationwide "as a result of the loss of patent protection from two of its best-selling drugs: Cymbalta and Evista," writes Susan Fracasso, Rapid Response Coordinator for the state of Connecticut in Wethersfield. "Those two products will be made generically, likely by facilities outside of the United States.
There are no replies in this thread yet. Be the first to post a reply below: